Weis Markets Delays Filing of 10-K Annual Report
Weis Markets announced that it will delay the filing of its Annual Report on Form 10-K for the 52-week fiscal year ended December 27, 2025. The filing is delayed because the company requires additional time to complete a review and analysis of the impact to, and associated restatement of, its historical financial statements related to the incorrect recording of certain overstated inventory amounts. The company continues to work diligently to complete the remaining review and restatement procedures. The company expects to file its Annual Report on Form 10-K for the 52-week fiscal year ended December 27, 2025, including all required restated financial statements, no later than March 12, 2026; however, the timing of the filing may be subject to further delay, and the company cannot provide assurance regarding the definitive filing date while this work remains in progress. At this time, the company estimates that the incorrect recording of overstated inventory is up to $22M as of the quarter ended September 27, 2025 which is an aggregation of an error that accumulated over multiple reporting periods. As of the quarter ended September 27, 2025, the aggregated estimate amount represents approximately 6.7% of Inventories within Current Assets and approximately 1.1% of Total Assets on the Consolidated Balance Sheet. These estimated adjustments are preliminary, and while the Company currently expects to report such estimated adjustments, there can be no assurance that the final adjustments made as part of any restatement will not differ materially from these estimates. In the interest of providing shareholders with relevant and timely information, the company is disclosing certain preliminary unaudited net sales results. Net sales and other revenue totaled $4.96B for the 52-week fiscal year ended December 27, 2025, compared with $4.79B for the 52-week fiscal year ended December 28, 2024, an increase of 3.5%. Fiscal year 2025 comparable store sales excluding fuel increased 2.1% on an individual year-over-year basis and increased 4% on a two-year stacked basis.
Trade with 70% Backtested Accuracy
Analyst Views on WMK
About WMK
About the author

- Stable Dividend Returns: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting value investors in uncertain markets due to its consistent cash flow.
- Competitive Market Advantage: Ingles Markets operates hundreds of supermarkets in the Southeast and owns its own dairy processing facility; despite facing activist shareholder challenges, its vertical integration may unlock value for the company.
- Strategic Acquisition Plan: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance its competitive edge in the healthcare market.
- Market Volatility Response: In the current uncertain market, Weis, Ingles, and Prestige exemplify durability, cash flow, and relevance during economic downturns, prompting investors to cautiously observe and gradually build positions.
- Stable Dividend Yield: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting investors seeking safe investments in uncertain market conditions.
- Value Investment Opportunity: Weis shares trade at a P/E ratio of about 15.6, below the consumer retail industry average of 19.2, and the recent drop below the 200-day moving average signals potential buying interest from value-oriented investors.
- Acquisition Driving Growth: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance the company's international presence in the health care market, likely boosting future revenue.
- Shareholder Activism Catalyst: Ingles Markets is facing a challenge from investment firm Summer Road LLC, which could act as a catalyst for unlocking value, although investors should proceed cautiously and consider gradual accumulation to mitigate potential risks.
- Financial Restatement Announcement: Weis Markets disclosed on February 26, 2026, via an 8-K filing that its audited financial statements for fiscal years 2022 to 2024 will be restated due to inaccurately recorded inventory, which could impact the company's financial transparency and investor confidence.
- Stock Price Decline Impact: Following the announcement, Weis Markets' shares fell by $5.12, or approximately 7.16%, from $71.51 on February 25, 2026, indicating heightened market concerns over the company's financial health and potentially prompting investor sell-offs.
- Legal Rights Investigation: The law firm Bragar Eagel & Squire is investigating whether Weis Markets violated federal securities laws, and if negative findings arise, the company may face lawsuits and liability, further affecting its market performance.
- Investor Contact Information: The firm encourages affected Weis Markets shareholders to reach out for more information, highlighting the potential risks the company faces in legal matters, which could impact future financing and shareholder relations.
- Financial Restatement Announcement: On February 26, 2026, Weis Markets disclosed to the SEC that financial statements for fiscal years 2022 through 2024 will be restated due to inaccurately recorded and overstated inventory, which will impact the company's financial transparency and investor confidence.
- Stock Price Plunge: Following the restatement announcement, Weis Markets' stock price fell by $5.12, a decline of 7.16%, closing at $66.39, reflecting market concerns over the company's financial health and investor panic.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Weis Markets and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to legal liabilities and further damage its market reputation.
- Annual Report Delay: Weis Markets announced a delay in filing its 2025 Annual Report until the financial review and restatement process is completed, which may affect investor expectations and confidence regarding the company's future performance.
- Financial Restatement Announcement: On February 26, 2026, Weis Markets disclosed to the SEC that its financial statements for fiscal years 2022 to 2024 would be restated due to inaccurately recorded and overstated inventory, raising significant investor concerns.
- Stock Price Volatility: Following the announcement of the financial restatement, Weis Markets' stock price fell by $5.12, a decline of 7.16%, closing at $66.39, indicating market apprehension regarding the company's financial transparency.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Weis Markets and its executives have engaged in securities fraud or other unlawful business practices, advising investors to contact the firm for more information, highlighting potential legal risks that could impact the company's future operations.
- Annual Report Filing Delay: The company announced a delay in filing its 2025 Annual Report until the review and restatement process is completed, which may further undermine investor confidence and exert additional pressure on the company's stock price.
- Financial Restatement Announcement: On February 26, 2026, Weis Markets disclosed to the SEC that its audited financial statements for fiscal years 2022 to 2024 and interim statements for 2025 will be restated due to inaccurately recorded and overstated inventory, raising significant investor concerns.
- Stock Price Reaction: Following the announcement, Weis Markets' stock price fell by $5.12, a decline of 7.16%, closing at $66.39 per share, reflecting market apprehension regarding the company's financial transparency and potential legal risks.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Weis Markets and its executives engaged in securities fraud or other unlawful business practices, with investors advised to contact the firm to join the class action, potentially exposing the company to greater legal liabilities.
- Annual Report Delay: Weis Markets announced a delay in filing its 2025 Annual Report until the review and restatement process is completed, which may undermine investor confidence in the company's future financial health.










